Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2019-08-29, Stock:ABBV, The news for the past five days is as follows:
2019-08-22: NEWS1: Here's What You Should Know About AbbVie Inc.'s (NYSE:ABBV) 6.3% Dividend Yield.NEWS2: Synlogic Discontinues Development of SYNB1020, Stock Down.NEWS3: Synlogic Discontinues Development of SYNB1020, Stock Down.
2019-08-23: NEWS1: Amgen Presents Positive Data From Rituxan Biosimilar Study.NEWS2: Amgen Presents Positive Data From Rituxan Biosimilar Study.NEWS3: Pharma Stock Roundup: ABBV's Rinvoq Gets FDA Nod, BAYRY to Sell Animal Health Unit.NEWS4: Pharma Stock Roundup: ABBV's Rinvoq Gets FDA Nod, BAYRY to Sell Animal Health Unit.NEWS5: Amgen Presents Positive Data From Rituxan Biosimilar Study.NEWS6: Pharma Stock Roundup: ABBV's Rinvoq Gets FDA Nod, BAYRY to Sell Animal Health Unit.
2019-08-26: NEWS1: Lilly's Olumiant Meets Primary Endpoint in 3rd Eczema Study.NEWS2: Lilly's Olumiant Meets Primary Endpoint in 3rd Eczema Study.NEWS3: Why AbbVie (ABBV) is a Great Dividend Stock Right Now.NEWS4: Why AbbVie (ABBV) is a Great Dividend Stock Right Now.NEWS5: Lilly's Olumiant Meets Primary Endpoint in 3rd Eczema Study.NEWS6: Why AbbVie (ABBV) is a Great Dividend Stock Right Now.
2019-08-27: NEWS1: Should You Buy AbbVie for the Dividend?.NEWS2: Should You Buy AbbVie for the Dividend?.NEWS3: Should You Buy AbbVie for the Dividend?.NEWS4: Lilly's (LLY) Taltz Gets FDA Nod for Ankylosing Spondylitis.NEWS5: Lilly's (LLY) Taltz Gets FDA Nod for Ankylosing Spondylitis.NEWS6: Amgen to Buy Celgene's Otezla for $13.4B: Is it a Good Buy?.NEWS7: Amgen to Buy Celgene's Otezla for $13.4B: Is it a Good Buy?.NEWS8: Lilly's (LLY) Taltz Gets FDA Nod for Ankylosing Spondylitis.NEWS9: Amgen to Buy Celgene's Otezla for $13.4B: Is it a Good Buy?.NEWS10: AbbVie to Present at the Morgan Stanley Healthcare Conference.NEWS11: Why Jim Cramer's Negative Take on Pfizer Is Flat-Out Wrong.NEWS12: Why Jim Cramer's Negative Take on Pfizer Is Flat-Out Wrong.NEWS13: This dividend-stock strategy is for investors who want an attractive monthly income stream.NEWS14: Why Jim Cramer&apos;s Negative Take on Pfizer Is Flat-Out Wrong.
2019-08-28: NEWS1: UPDATE 1-FDA flags risks from AbbVie, Gilead, Merck hepatitis C drugs to certain patients.NEWS2: Bristol-Myers' Empliciti Gets EMA Nod for Label Expansion.NEWS3: Bristol-Myers' Empliciti Gets EMA Nod for Label Expansion.NEWS4: Bristol-Myers' Empliciti Gets EMA Nod for Label Expansion.

Answer: Rise